02:49 , Jan 5, 2019 |  BioCentury  |  Finance

Ready to launch

  The proposed $74 billion takeout of Celgene Corp. by Bristol-Myers Squibb Co. will not shift buysider attention away from upcoming and maturing drug launches heading into 2019, with plenty to track following a record...
20:17 , Aug 16, 2017 |  BC Innovations  |  Emerging Company Profile

Aiming horizontal

SciBac Inc. is using old-school genetics to make therapeutic bacteria that can battle pathogenic organisms and antibiotic-resistant infections. The approach uses horizontal gene transfer to move therapeutic genes from newly discovered species into strains already...
08:00 , Dec 15, 2014 |  BC Week In Review  |  Company News

Cubist, Merck deal

Merck will acquire Cubist for $102 per share and $1.1 billion in assumption of debt in a deal valued at $9.5 billion. The cash offer of $102 per share, or $8.4 billion, represents a 37%...
08:00 , Dec 15, 2014 |  BioCentury  |  Finance

Uphill road for Cubist CVRs

When Merck & Co. Inc. (NYSE:MRK) acquires Cubist Pharmaceuticals Inc. (NASDAQ:CBST), the pharma will take over the contingent value rights the infectious disease company owes the former shareholders of Optimer Pharmaceuticals Inc. and Trius Therapeutics...
01:56 , Nov 27, 2014 |  BC Extra  |  Clinical News

Astellas: Data show fidaxomicin's efficacy, cost savings

Astellas Pharma Inc. (Tokyo:4503) said a pooled analysis showed that patients receiving fidaxomicin to treat Clostridium difficile infection (CDI) had reduced mortality, recurrence rates and healthcare costs compared with standard-of-care (SOC) vancomycin and metronidazole ....
07:00 , Apr 28, 2014 |  BioCentury  |  Finance

Venture hots up

Private biotechs have raised $3.1 billion since the start of the year, double the $1.5 billion raised in the same period last year. At least one investor contacted by BioCentury expects the pace to continue...
08:00 , Jan 27, 2014 |  BioCentury  |  Finance

Taiwan's biotech boom

As Taiwan's traditional growth sectors in IT, electronics and manufacturing have cooled, local investors have begun to look for new places to invest. Many are betting biotech is the next big thing. Indeed, the last...
08:00 , Nov 25, 2013 |  BioCentury  |  Finance

Bugs in the clinic

Bugs in the clinic Newco Seres Health Inc. has emerged from stealth mode, and the Flagship Ventures startup believes it already has at least one leg up on other microbiome companies - a program in...
08:00 , Nov 4, 2013 |  BC Week In Review  |  Clinical News

Dificid fidaxomicin regulatory update

The European Society of Clinical Microbiology and Infectious Diseases (ESCMID) published new guidelines recommending fidaxomicin for Clostridium difficile infection (CDI) in all patients suitable for oral antibiotic treatment. Specifically, fidaxomicin is recommended as first-line therapy...
07:00 , Oct 28, 2013 |  BC Week In Review  |  Company News

Cubist, Optimer deal

Cubist completed the acquisition of Optimer in a deal valued at up to $801 million. Optimer received about $551 million up front in cash and a tradable contingent value right (CVR) for a one-time payment...